Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.

Daijiro HaradaHideko IsozakiToshiyuki KozukiToshihide YokoyamaHiroshige YoshiokaAkihiro BesshoShinobu HosokawaIchiro TakataNagio TakigawaKatsuyuki HottaKatsuyuki Kiuranull null

Published in: Thoracic cancer (2021)

Although the desired response rate was not achieved, crizotinib monotherapy following treatment with alectinib showed efficacy alongside previously described adverse events.

Keyphrases

advanced non small cell lung cancer
combination therapy
open label
genome wide
clinical trial
gene expression
newly diagnosed
transcription factor
genome wide analysis